J&J (NYSE:JNJ) stock surges rallying peers despite Trump's latest tariff threats on pharma as the company posts a quarterly ...

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

GSK PLC closed 15.32% short of its 52-week high of £16.79, which the company reached on September 9th.

UK pharma major GSK is seeking US approval for Blenrep (belantamab mafodotin) in two multiple myeloma indications.

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains ...

GSK's blood cancer drug, Blenrep, is under the U.S. Food and Drug Administration (USFDA) spotlight, as staff reviewers raised ...

Recent health headlines include FDA's eye safety concerns over GSK's cancer drug, escalating malnutrition rates in Gaza ...

The U.S. Food and Drug Administration's reviewers on Wednesday raised efficacy concerns over the use of Otsuka Pharma's drug in combination with Viatris' Zoloft for the treatment of adults with PTSD.

From my colleague Drew Joseph: Ahead of an advisory committee meeting Thursday focused on GSK’s multiple myeloma drug Blenrep, the FDA pointed to concerns about the high rates of eye issues that have ...